









































# Pharmaceuticals – Pipeline Overview<sup>1</sup> (as of July 31, 2024)

| Phase I   | Phase II  | Phase III  |
|---|---|--|
| HER2/mEGFR Inhibitor (BAY 2927088)  ●                                    | Congestive Heart Failure rAAV Gene Therapy (AB-1002)  ●<br># Congestive Heart Failure (GenePHIT) | Darolutamide (AR Inhibitor)  ○<br># Prostate Cancer (mHSPC) (ARANOTE)<br># Adjuvant Prostate Cancer (DASL-HiCaP)<br># Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP) |
| DGKzeta Inhibitor (BAY 2965501)  ●                                       |   |  |
| CCR8 Ab (BAY 3375968)  ●   | Anti-α2AP (BAY 3018250)  ●<br># Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)               | Finerenone (MR Antagonist)  ○<br># Heart Failure (HFmr/pEF) (FINEARTS-HF)<br># Non-diabetic Chronic Kidney Disease (FIND-CKD)<br># Chronic Kidney Disease in Type 1 Diabetes (FINE-ONE)                 |
| VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)  ●                  | Parkinson's Disease rAAV Gene Therapy (AB-1005)  ●<br># Parkinson's Disease (REGENERATE-PD)      |  |
| DGKalpha Inh (BAY 2862789)  ●  |   |  |
| 225Ac-Pelgifatamab (BAY 3546828)  ●                                      |   | Vericiguat (sGC Stimulator)  ○<br># Heart Failure (HFREF) (VICTOR <sup>2</sup> )  |
| VVD STAT3 Inhibitor (VVD-130850, BAY 3630914)  ●                         |   | Asundexian (FXIa Inhibitor)  ●<br># 2 <sup>o</sup> Stroke Prevention (OCEANIC-STROKE)   |
| 225Ac-PSMA-Trillium (BAY 3563254)  ●                                     |   | Aflibercept 8mg (VEGF Inhibitor)  ○<br># Retinal Vein Occlusion (QUASAR)  |
| sGC Activator Oral (BAY 3283142)  ●                                      |   | Gadoquatrane (High Relaxivity Contrast Agent)  ●<br># Magnetic Resonance Imaging (QUANTI-CNS, QUANTI-OB)             |
| SEMA 3a (BAY 3401016)  ●   |   |  |
| Anti-coagulant (BAY 3389934)  ●  |   |  |
| Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01)  ●           |   |  |
| Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)  ● |   |  |
| Pompe Disease rAAV Gene Therapy (ACTUS-101)  ●                           |   |  |
| Huntington's Disease rAAV Gene Therapy (AB-1001 aka BV-101)  ●           |   |  |
| LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)  ●                  |   |  |
| GPR84 Antagonist (BAY 3178275)  ●                                      |   |  |
| BAY 2701250  ●   |   |  |
| <b>Submissions</b>  |   |  |
|   | Elinzanetant (Neurokinin-1,3 Rec Antagonist)  ●<br># US: Vasomotor Symptoms                      |  |
|   | Aflibercept 8mg (VEGF-Inhibitor)  ○<br># CN: Neovasc. Age-rel. Macular Degen. (nAMD)           |  |
|   | Acoramidis <sup>4</sup> (TTR-Stabilizer)  ●<br># EU: Transthyretin Amyloid Cardiomyopathy      |  |

-  Oncology
-  Cardiovascular+<sup>3</sup>
-  Neurology & Rare Diseases
-  Immunology
-  Others

-  New molecular entity
-  Life cycle management



<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit  
<sup>2</sup> Conducted by Merck & Co <sup>3</sup> Including Precision Cardiovascular, Nephrology & Acute Care  
<sup>4</sup> Exclusive commercialization rights acquired for EU markets; pending marketing authorization approval. Submission to EMA under responsibility of BridgeBio